Substance / Medication

OnabotulinumtoxinA

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

13 trials linked to this intervention

13
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
OnabotulinumtoxinA in the Management of Pain in Adult Patients with Spasticity: A Systematic Literature Review.
Bianchi Francesca, Nelson Mariana, Wissel Jörg et al. · Toxins (Basel) · 2025
PMID: 40864094Meta-AnalysisFull text (PMC)
Efficacy and safety of onabotulinumtoxinA in the treatment of medication overuse headache: a systematic review.
Lang Hui, Peng Cheng, Wu Kongyuan et al. · Front Neurol · 2024
PMID: 39372702Meta-AnalysisFull text (PMC)
Treatment with OnabotulinumtoxinA for Oromandibular Dystonia: A Systematic Review and Meta-Analysis.
Yoshida Kazuya, Kaji Ryuji · Toxins (Basel) · 2024
PMID: 39728804Meta-AnalysisFull text (PMC)
Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review.
Mavridi Artemis, Redmond Aine, Archontakis-Barakakis Paraschos et al. · Toxins (Basel) · 2024
PMID: 39057935Meta-AnalysisFull text (PMC)
Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review.
Shaterian Negar, Shaterian Negin, Ghanaatpisheh Aref et al. · Pain Res Manag · 2022
PMID: 35401888Meta-AnalysisFull text (PMC)
Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis.
Shawer Sami, Khunda Aethele, Waring Gareth J et al. · Int Urogynecol J · 2022
PMID: 35024885Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
OnabotulinumtoxinA (substance)
SNOMED CT
444627005
UMLS CUI
C2719767

Clinical Data

This intervention maps to 7 entities in the Ltrl knowledge graph.

7
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
13
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.